IN VIVO ROLE OF CTLA-4 IN COSTIMULATION AND AUTOIMMUNITY
CTLA-4 在协调刺激和自身免疫中的体内作用
基本信息
- 批准号:2871547
- 负责人:
- 金额:$ 23.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-02-01 至 2002-01-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION: (Adapted from the Investigator's abstract): The investigator
will test the hypothesis that CTLA-4 downregulates T-cell activation and is
normally involved in the prevention of autoimmunity. Evidence for this
premise comes from the investigator's finding that the CTLA-4-deficient mice
develop splenomegaly and lymphadenopathy, multi-organ lymphocytic
infiltration and tissue destruction with severe myocarditis and
pancreatitis, and die by 3-4 weeks of age. Three specific aims will be
tested. The role of CTLA-4 in regulation of T-cell dependent immune
responses will be analyzed by determining how CTLA-4 deficiency affects
T-cell responses in vitro and whether CTLA-4 mediates its inhibitory effects
solely through interactions with B7-1 and B7-2. The mechanisms of
CTLA-4-mediated inhibition will be studied using naive and activated T-cells
from CTLA-4-deficient, TCR transgenic mice. Emphasis will be placed on
susceptibility to apoptosis and lymphokine production. The contribution of
CTLA-4 to systemic autoimmune responses will be addressed by assessment of
the pathology of in CTLA-4-deficient mice, determination of whether
self-reactive T-cells appear in CTLA-4-deficient mice, and whether the
course of EAE in MBP-specific TCR transgenic mice is altered when these mice
lack CTLA-4.
描述:(改编自研究者摘要):研究者
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Arlene H. Sharpe其他文献
The complexity of the B7-CD28/CTLA-4 costimulatory pathway.
B7-CD28/CTLA-4 共刺激途径的复杂性。
- DOI:
- 发表时间:
1998 - 期刊:
- 影响因子:0
- 作者:
Schweitzer An;Arlene H. Sharpe - 通讯作者:
Arlene H. Sharpe
Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8sup+/sup T cells
肿瘤细胞通过改变 CD8+T 细胞中的丙酮酸利用和琥珀酸盐信号来决定抗肿瘤免疫反应
- DOI:
10.1016/j.cmet.2022.06.008 - 发表时间:
2022-08-02 - 期刊:
- 影响因子:30.900
- 作者:
Ilaria Elia;Jared H. Rowe;Sheila Johnson;Shakchhi Joshi;Giulia Notarangelo;Kiran Kurmi;Sarah Weiss;Gordon J. Freeman;Arlene H. Sharpe;Marcia C. Haigis - 通讯作者:
Marcia C. Haigis
Age-associated remodeling of T cell immunity and metabolism
T 细胞免疫和代谢的年龄相关重塑
- DOI:
10.1016/j.cmet.2022.11.005 - 发表时间:
2023-01-03 - 期刊:
- 影响因子:30.900
- 作者:
SeongJun Han;Peter Georgiev;Alison E. Ringel;Arlene H. Sharpe;Marcia C. Haigis - 通讯作者:
Marcia C. Haigis
The B7:CD28 family and friends: Unraveling coinhibitory interactions
B7:CD28 家族及朋友:解开共抑制相互作用
- DOI:
10.1016/j.immuni.2024.01.013 - 发表时间:
2024-02-13 - 期刊:
- 影响因子:26.300
- 作者:
Kelly P. Burke;Apoorvi Chaudhri;Gordon J. Freeman;Arlene H. Sharpe - 通讯作者:
Arlene H. Sharpe
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
PD-L2 是 PD-1 的第二种配体,可抑制 T 细胞活化
- DOI:
10.1038/85330 - 发表时间:
2001-03-01 - 期刊:
- 影响因子:27.600
- 作者:
Yvette Latchman;Clive R. Wood;Tatyana Chernova;Divya Chaudhary;Madhuri Borde;Irene Chernova;Yoshiko Iwai;Andrew J. Long;Julia A. Brown;Raquel Nunes;Edward A. Greenfield;Karen Bourque;Vassiliki A. Boussiotis;Laura L. Carter;Beatriz M. Carreno;Nelly Malenkovich;Hiroyuki Nishimura;Taku Okazaki;Tasuku Honjo;Arlene H. Sharpe;Gordon J. Freeman - 通讯作者:
Gordon J. Freeman
Arlene H. Sharpe的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Arlene H. Sharpe', 18)}}的其他基金
Defining regulators of immunity to acute infection using CRISPR screens
使用 CRISPR 筛选定义急性感染免疫调节因子
- 批准号:
10210502 - 财政年份:2020
- 资助金额:
$ 23.23万 - 项目类别:
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
简化靶向治疗可提高抗 PD-1 抑制剂对黑色素瘤的疗效
- 批准号:
10153453 - 财政年份:2018
- 资助金额:
$ 23.23万 - 项目类别:
Project 2: Measuring and modeling the tumor and immune microenvironment before and during therapy and at the time of drug resistance
项目2:治疗前、治疗期间以及耐药时的肿瘤和免疫微环境的测量和建模
- 批准号:
10343840 - 财政年份:2018
- 资助金额:
$ 23.23万 - 项目类别:
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
简化靶向治疗可提高抗 PD-1 抑制剂对黑色素瘤的疗效
- 批准号:
9906872 - 财政年份:2018
- 资助金额:
$ 23.23万 - 项目类别:
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
简化靶向治疗可提高抗 PD-1 抑制剂对黑色素瘤的疗效
- 批准号:
9576657 - 财政年份:2018
- 资助金额:
$ 23.23万 - 项目类别:
Defining regulators of immunity to acute infection using CRISPR screens
使用 CRISPR 筛选定义急性感染免疫调节因子
- 批准号:
10207344 - 财政年份:2017
- 资助金额:
$ 23.23万 - 项目类别:
Project 1: CRISPR screens to discover regulators of CD8 and CD4 cell fates and function
项目 1:通过 CRISPR 筛选发现 CD8 和 CD4 细胞命运和功能的调节因子
- 批准号:
10207349 - 财政年份:2017
- 资助金额:
$ 23.23万 - 项目类别:
Defining regulators of immunity to acute infection using CRISPR screens
使用 CRISPR 筛选定义急性感染免疫调节因子
- 批准号:
9380804 - 财政年份:2017
- 资助金额:
$ 23.23万 - 项目类别: